Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

204 ARTÍCULOS , VIENDO DEL 151 AL 165

Tau PET Imaging for Staging of Alzheimer's Disease in Down Syndrome

Rafii MS.

Dev Neurobiol. 2019 Jul;79(7):711-715. doi: 10.1002/dneu.22658. Epub 2018 Dec 16.

Long-Lasting Neuropsychological Effects of a Computerized Cognitive Training in Patients Affected by Early Stage Alzheimer's Disease: Are They Stable Over Time?

Cavallo M, Angilletta C.

J Appl Gerontol. 2019 Jul;38(7):1035-1044. doi: 10.1177/0733464817750276. Epub 2018 Jan 2.

Monotherapy Is Good Enough for Patients with Mild-to-Moderate Alzheimer's Disease: A Network Meta-analysis of 76 Randomized Controlled Trials

Tsoi KK, Chan JY, Chan FC, Hirai HW, Kwok TC, Wong SY.

Clin Pharmacol Ther. 2019 Jan;105(1):121-130. doi: 10.1002/cpt.1104. Epub 2018 Jun 19.

Drug development for Alzheimer's disease: review

Lao K, Ji N, Zhang X, Qiao W, Tang Z, Gou X.

J Drug Target. 2019 Feb;27(2):164-173. doi: 10.1080/1061186X.2018.1474361. Epub 2018 Jun 20.

An expanded theory of Alzheimer's caregiving

Lang SF, Fowers BJ.

Am Psychol. 2019 Feb-Mar;74(2):194-206. doi: 10.1037/amp0000323. Epub 2018 May 24.

Neuro-nutrients as anti-alzheimer's disease agents: A critical review

Ravi SK, Narasingappa RB, Vincent B.

Crit Rev Food Sci Nutr. 2019;59(18):2999-3018. doi: 10.1080/10408398.2018.1481012. Epub 2018 Jun 21.

Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Bapineuzumab: A Single-Ascending-Dose Study in Patients With Mild to Moderate Alzheimer Disease

Lu M, Brashear HR.

Clin Pharmacol Drug Dev. 2019 Apr;8(3):326-335. doi: 10.1002/cpdd.584. Epub 2018 Jun 19.

Pharmacokinetics, Safety, Tolerability, and Pharmacodynamics of Alicapistat, a Selective Inhibitor of Human Calpains 1 and 2 for the Treatment of Alzheimer Disease: An Overview of Phase 1 Studies

Lon HK, Mendonca N, Goss S, Othman AA, Locke C, Jin Z, Rendenbach-Mueller B.

Clin Pharmacol Drug Dev. 2019 Apr;8(3):290-303. doi: 10.1002/cpdd.598. Epub 2018 Jul 27.

Management of behavioral and psychological symptoms in people with Alzheimer's disease: an international Delphi consensus

Kales HC, Lyketsos CG, Miller EM, Ballard C.

Int Psychogeriatr. 2019 Jan;31(1):83-90. doi: 10.1017/S1041610218000534. Epub 2018 Aug 2.

Neural correlates of liraglutide effects in persons at risk for Alzheimer's disease

Watson KT, Wroolie TE, Tong G, Foland-Ross LC, Frangou S, Singh M, McIntyre RS, Roat-Shumway S, Myoraku A, Reiss AL, Rasgon NL.

Behav Brain Res. 2019 Jan 1;356:271-278. doi: 10.1016/j.bbr.2018.08.006. Epub 2018 Aug 9.

Effect and Safety of Huannao Yicong Formula () in Patients with Mild-to-Moderate Alzheimer's Disease: A Randomized, Double-Blinded, Donepezil-Controlled Trial

Yang Y, Liu JP, Fang JY, Wang HC, Wei Y, Cao Y, Liu JG, Liu LT, Li H.

Chin J Integr Med. 2019 Aug;25(8):574-581. doi: 10.1007/s11655-018-3054-7. Epub 2018 Aug 14.

Targeting Neuroinflammation as a Therapeutic Strategy for Alzheimer's Disease: Mechanisms, Drug Candidates, and New Opportunities

Fu WY, Wang X, Ip NY.

ACS Chem Neurosci. 2019 Feb 20;10(2):872-879. doi: 10.1021/acschemneuro.8b00402. Epub 2018 Sep 17.

The effect of reminiscence therapy on cognitive functions, depression, and quality of life in Alzheimer patients: Randomized controlled trial

Lök N, Bademli K, Selçuk-Tosun A.

Int J Geriatr Psychiatry. 2019 Jan;34(1):47-53. doi: 10.1002/gps.4980. Epub 2018 Sep 24.

Effects of Hand Exercise on Eating Action in Patients With Alzheimer's Disease

Chen LL, Li H, Chen XH, Jin S, Chen QH, Chen MR, Li N.

Am J Alzheimers Dis Other Demen. 2019 Feb;34(1):57-62. doi: 10.1177/1533317518803722. Epub 2018 Oct 9.

Essential Oils as Treatment Strategy for Alzheimer's Disease: Current and Future Perspectives

Benny A, Thomas J.

Planta Med. 2019 Feb;85(3):239-248. doi: 10.1055/a-0758-0188. Epub 2018 Oct 25.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias